Jump to section
To empower every person to improve their life through their DNA.
Helix is a population genomics company working at the intersection of clinical care, research, and genomics. The end-to-end platform produced by Helix enables healthcare systems to achieve better outcomes, while also providing valuable information for life science companies. Understanding genetics is a valuable tool for businesses as they can deliver products and services that are designed specifically for the individual DNA of consumers, drastically increasing their safety and effectiveness.
The Helix platform delivers some incredibly complex clinical research data, which makes it possible for a variety of businesses to gain genetic insight. The company also stores data in large quantities, making it flexible and readily accessible for its clients.
Many companies are working in the space such as 23andMe, MyHeritage, Orig3n and Ancestry. They are all fighting for a share of the genetics market, predicted to be worth $55 billion by 2025.
Freddie
Company Specialist at Welcome to the Jungle
Jun 2021
$50m
SERIES C
Jul 2020
$33m
GRANT
This company has top investors
James Lu
(CEO & Board Member)MD/PhD from Baylor College of Medicine. Senior Engineer at Merck, Research Fellow at Wellcome Trust. Co-founded Helix in 2015.
Operations & Strategy